Community Practice Connections™: Distinguishing Precision Pathways for c-Met and MET Alterations in NSCLC

Release Date: September 15, 2025

Expiration Date: September 15, 2026

Activity Overview

Several types of MET gene alterations are present in non–small cell lung cancer (NSCLC). Tyrosine kinase inhibitors have been approved for patients with NSCLC and a MET exon 14 skipping mutation. More recently, an antibody-drug conjugate targeting c-Met has been approved, in this case for patients with previously treated NSCLC and high c-Met protein overexpression. These developments underscore the need for physicians to understand the different classes of MET aberrations, as well as which classes of c-Met–targeted agents are available for each aberration.

This Community Practice Connection™ program provides an in-depth review of some of the key highlights from Distinguishing Precision Pathways for c-Met and MET Alterations in NSCLC, presented at the 26th Annual International Lung Cancer Congress®. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of testing patients for MET alterations and choosing the optimal treatment, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Target Audience

This educational activity is directed toward medical, surgical, and radiation oncologists interested in the treatment of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers and other health care professionals interested in the treatment of lung cancer are also invited to attend.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Assess optimal molecular testing strategies for individual categories of MET alterations in patients with NSCLC
• Evaluate safety and efficacy results from clinical trials investigating c-Met–targeted approaches for the management of patients with advanced NSCLC
• Apply recent data on c-Met–directed therapeutic approaches in the management of patients with NSCLC
• Develop approaches to manage common and severe adverse events associated with c-Met–directed therapies